No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RVNC240517P5000
- 1.76
- +0.91+107.06%
15min DelayClose May 10 16:00 ET
1.76High1.25Low
1.27Open0.85Pre Close11 Volume316 Open Interest5.00Strike Price1.65KTurnover310.00%IV-4.37%PremiumMay 17, 2024Expiry Date1.68Intrinsic Value100Multiplier6DDays to Expiry0.08Time Value100Contract SizeAmericanOptions Type-0.7764Delta0.2143Gamma1.82Leverage Ratio-0.0305Theta-0.0007Rho-1.41Eff Leverage0.0013Vega
Intraday
- 5D
- 1D
News
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
Revance Therapeutics Down Over 21%, on Pace for Largest Percent Decrease Since October 2021 -- Data Talk
Revance Therapeutics, Inc. (RVNC) is currently at $3.37, down $0.92 or 21.42% --Would be lowest close since April 25, 2024, when it closed at $3.29 --On pace for largest percent decrease since Oct.
NVAX, GRPN and MVIS Among Mid-day Movers
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out to
Express News | Revance Therapeutics Shares Are Trading Lower Following Mixed Q1 Earnings
Comments
$Revance Therapeutics(RVNC.US$ nice bounce
Despite strong revenue growth, the significant share price drop indicates potential unresolved company challenges. It's advised to scrutinize the stock and forecasts before purchase.
$Revance Therapeutics(RVNC.US$ Monday showed sales volumn rose 22% in Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. The firm predicted an unaudited Q4 and full-year 2023 revenue between $58 million and $59 million and $212 million and $213 million, representing approximately 28% and 80% YoY growth, respectively.
1
Concerns raised by insiders' stock selling. CEO Mark Foley's sale was price-wise favorable. Despite no recent insider purchase, the 1.9% insider stake suggests alignment with shareholders.
Read more